glp-1 conference Expert panel addresses RAs' factors, features, and future ASAM eLearning: Intervening with Women

This new filing reiterates the harms alleged by patients against the manufacturers of Wegovy and other weight loss drug manufacturers

Semaglutide for managing overweight and obesity recommendations (TA875)

doi: 10.2337/db10-0674

Key Biomarker and Clinical Factors to Assess Before Starting Before considering GLP-1 therapy, several clinical markers and disease characteristics should be evaluated together with your healthcare provider

Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents

The correlation between structural damage and symptoms is not established and thus constitutes a major challenge for the development of potential DMOADs [84]